Rafael Hlds

Rafael Holdings, Inc. owns interest in commercial real estate assets and clinical stage pharmaceutical companies. It operates through the Real Estate and Pharmaceuticals segments. The Real Estate segment refers to the real estate holdings. The Pharmaceuticals segment is comprised of debt interests and warrants in Rafael Pharmaceuticals and a majority equity interest in LipoMedix Pharmaceuticals. The company was founded in 2017 and is headquartered in Newark, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. It operates through the Healthcare, Infusion Technology and Real Estate segments. The Healthcare segment relates to the activities of LipoMedix, Barer, Farber, and Rafael Medical Devices. The company was founded in 2017 and is headquartered in Newark, NJ.

President and CEO Sanjeev Luther to discuss the status of clinical trials for lead compound CPI-613® (devimistat) and provide update on drug development pipeline President and CEO Sanjeev Luther to discuss the status of clinical trials for lead compound CPI-613® (devimistat) and provide update on drug development pipeline

Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference

Cranbury, NJ, Dec.  03, 2019  (GLOBE NEWSWIRE) --  Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Ariela Noy, M.D., hematologic oncologist at Memorial Sloan Kettering Cancer Center and principal investigator on a Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt lymphoma/leukemia or high-grade B-Cell lymphoma, will lead a poster presentation at the 61st Annual American Society of Hematology (ASH) Meeting and Exposition. 

Data on Rafael Pharmaceuticals’ CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition

Cranbury, NJ, Dec.  03, 2019  (GLOBE NEWSWIRE) --  Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Co-Chief Medical Officer, Timothy Pardee, M.D., Ph.D., will lead a poster presentation on the Phase 3 study of CPI-613® (devimistat) for the treatment of older patients with relapsed or refractory acute myeloid leukemia (AML) at the 61st Annual ASH Meeting and Exposition. 

Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos

Cranbury, N.J., Dec.  02, 2019  (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia. The clinical trial will begin enrolling patients at Massachusetts General Hospital in Boston starting this month. The trial is currently underway at Memorial Sloan Kettering Cancer Center in New York City and at City of Hope in Duarte, California. 

Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston

Cranbury, NJ, Nov.  07, 2019  (GLOBE NEWSWIRE) --  Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has joined the Scientific & Medical Affairs Industry Membership of the Pancreatic Cancer Action Network (“PanCAN”), a worldwide leader in the fight against pancreatic cancer. Rafael will join other industry members, PanCAN’s Scientific and Medical Advisory Board and global leaders in the pursuit of improving outcomes for pancreatic cancer patients. 

Rafael Pharmaceuticals  Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership

Dr. Costa Filho joins alongside Timothy Pardee, M.D., Ph.D, who will remain as Co-Chief Medical Officer Dr. Costa Filho joins alongside Timothy Pardee, M.D., Ph.D, who will remain as Co-Chief Medical Officer

Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D.

Cranbury, NJ, Oct.  28, 2019  (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the milestone activation of 25 sites for its pivotal Phase 3 clinical trial (ARMADA 2000) of CPI-613® (devimistat) in patients with relapsed or refractory acute myeloid leukemia (AML). The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone (CHAM) in older patients with relapsed or refractory AML. The global study is now active at sites in the United States, Austria, Spain and South Korea, with more openings to come.

Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cranbury, NJ, Oct.  24, 2019  (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the Phase 3 clinical trial (PANC 003) of CPI-613® (devimistat) for patients with metastatic pancreatic cancer is now active in four sites in South Korea.

Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, Oct.  17, 2019  (GLOBE NEWSWIRE) --   Rafael Pharmaceuticals, Inc.  (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has entered into a collaboration with the National Cancer Institute (NCI), part of the  National Institutes of Health  (NIH). This collaboration will test CPI-613® (devimistat), Rafael’s first-in-class clinical lead compound, in cytokine independent (acute) HTLV-1 (human T-cell leukemia virus type 1) associated adult T-cell leukemia/lymphoma. Rafael will provide the compound for the study.

Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma

CRANBURY, N.J., Sept.  19, 2019  (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the Phase 3 clinical trial (ARMADA 2000) of CPI-613® (devimistat) in older patients with relapsed or refractory acute myeloid leukemia (AML) is now active and enrolling patients in South Korea. The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of its lead compound devimistat in combination with high dose cytarabine and mitoxantrone (CHAM). The clinical trials will kick off with an investigator meeting held on Sept. 19 in Seoul.

Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

CRANBURY, N.J., Sept.  17, 2019  (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 3 clinical trial for patients with metastatic pancreatic cancer (AVENGER 500) into France. AVENGER 500 is a global, multicenter, open-label, randomized pivotal trial that is evaluating the efficacy and safety of CPI-613®️ (devimistat), Rafael’s lead compound, in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients with metastatic adenocarcinoma of the pancreas. This announcement comes on the heels of the trial’s expansion into Israel. The trial will open in 13 sites throughout France, with enrollment already underway in select locations.

Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that peer-reviewed medical journal Future Oncology published two manuscripts about cancer metabolism and the company’s lead drug candidate CPI-613® (devimistat).

Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat)

News for Rafael Hlds Stock (RFL)